Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its target price lifted by stock analysts at Citigroup Inc. to $575.00 in a research note issued to investors on Friday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective would indicate a potential upside of 22.66% from the company’s previous close.

A number of other equities analysts have also weighed in on REGN. Sanford C. Bernstein reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, May 25th. Piper Jaffray Companies reissued an “overweight” rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, August 1st. Leerink Swann reissued an “outperform” rating and issued a $493.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, June 13th. BMO Capital Markets reissued a “hold” rating and issued a $421.00 target price (up previously from $412.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, May 5th. Finally, Barclays PLC reissued an “equal weight” rating and issued a $450.00 target price (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a research report on Saturday, July 22nd. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $477.91.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.35% during mid-day trading on Friday, hitting $468.76. 771,168 shares of the stock traded hands. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The company’s 50-day moving average price is $499.60 and its 200 day moving average price is $421.63. The company has a market capitalization of $49.49 billion, a PE ratio of 56.74 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s revenue was up 21.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.82 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals will post $13.63 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT Raised to $575.00 at Citigroup Inc.” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/06/regeneron-pharmaceuticals-inc-nasdaqregn-pt-raised-to-575-00-at-citigroup-inc.html.

In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the completion of the transaction, the chairman now directly owns 414,156 shares in the company, valued at approximately $189,741,429.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares of the company’s stock, valued at $23,405,572.50. The disclosure for this sale can be found here. Insiders sold a total of 59,396 shares of company stock valued at $28,484,734 over the last 90 days. 10.40% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System increased its position in Regeneron Pharmaceuticals by 1.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 115,325 shares of the biopharmaceutical company’s stock valued at $56,641,000 after buying an additional 1,087 shares during the last quarter. Fortaleza Asset Management Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at $300,000. Jennison Associates LLC increased its position in Regeneron Pharmaceuticals by 74.1% in the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock valued at $634,977,000 after buying an additional 550,247 shares during the last quarter. BB&T Securities LLC increased its position in Regeneron Pharmaceuticals by 52.9% in the second quarter. BB&T Securities LLC now owns 2,496 shares of the biopharmaceutical company’s stock valued at $1,225,000 after buying an additional 864 shares during the last quarter. Finally, Nippon Life Insurance Co. increased its position in Regeneron Pharmaceuticals by 39.6% in the second quarter. Nippon Life Insurance Co. now owns 5,030 shares of the biopharmaceutical company’s stock valued at $2,470,000 after buying an additional 1,428 shares during the last quarter. Institutional investors and hedge funds own 66.79% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.